RSS Atossa's 1 MG Z-Endoxifen Shows Reduction In Dense Breast Tissue In Premenopausal Women

Currently reading:
 RSS Atossa's 1 MG Z-Endoxifen Shows Reduction In Dense Breast Tissue In Premenopausal Women

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
6,211
Likes
1,916
Credits
32,784©
Cash
0$
Atossa Therapeutics, Inc. (ATOS) announced on Wednesday the results of their Phase 2 KARISMA-Endoxifen trial. This study focused on assessing the safety and tolerability of Endoxifen in lowering mammographic breast density (MBD) among pre-menopausal women at risk for breast cancer.

The trial was a randomized, double-blind, and placebo-controlled study, involving 240 premenopausal women between the ages of 40 and 55. Participants were divided into three groups: one receiving a placebo, and two others receiving either 1 mg or 2 mg of daily oral Z-endoxifen for a six-month period.

According to the data, the group receiving 1 mg of Z-endoxifen experienced a 17.3 percentage point reduction in MBD, while the 2 mg group saw a more significant reduction of 23.5 percentage points. In contrast, the placebo group had only a negligible change in MBD, marked at 0.27 percentage points.

However, the study also highlighted that the 2 mg dosage was linked to an increased incidence of side effects such as hot flashes, night sweats, and vaginal discharge.

These findings suggest that Z-endoxifen holds promise as a preventive treatment for women with dense breast tissue. Currently, Atossa's shares are trading at $1.29 on the Nasdaq, reflecting a 2.78 percent increase.

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips
Top Bottom